Efficacy and Safety of Teriflunomide in Multiple Sclerosis across Age Groups: Analysis from Pooled Pivotal and Real-world Studies
Background: Evidence suggests that efficacy and safety of disease-modifying treatments for multiple sclerosis may differ with age. We evaluate efficacy and safety of teriflunomide across age subgroups of patients from pooled clinical trials and real-world studies. Methods: Post hoc analyses of patie...
Main Authors: | Jiwon Oh, Sandra Vukusic, Klaus Tiel-Wilck, Jihad Said Inshasi, David Rog, Darren P Baker, Yelena Pyatkevich, Elizabeth M Poole, Patrick Vermersch |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-07-01
|
Series: | Journal of Central Nervous System Disease |
Online Access: | https://doi.org/10.1177/11795735211028781 |
Similar Items
-
Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study
by: Boris A. Kallmann, et al.
Published: (2019-03-01) -
Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects
by: Jiwon Oh, et al.
Published: (2014-09-01) -
An update of teriflunomide for treatment of multiple sclerosis
by: Oh J, et al.
Published: (2013-04-01) -
Teriflunomide in patients with multiple sclerosis
by: N. Y. Lasch, et al.
Published: (2015-12-01) -
Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis
by: Giancarlo Comi, et al.
Published: (2020-10-01)